Zimmer Biomet Holdings, Inc. entered into two new unsecured revolving credit agreements on June 26, 2026. The first is a $1.5 billion five-year facility maturing June 26, 2031, which includes an uncommitted $750 million incremental feature. The second is a $1.25 billion 364-day facility maturing June 25, 2027. Both agreements, administered by JPMorgan Chase Bank, N.A., carry a consolidated indebtedness to EBITDA ratio covenant of 4.5 to 1.0, potentially increasing to 5.0 to 1.0 for certain acquisitions. These new facilities replaced existing 2025 credit agreements that had no outstanding principal balance. Zimmer Biomet is a medical technology company that manufactures orthopedic products.